13F Holdings
中文EN

XLO Xilio Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1840233 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY73.0%
TTM net income YoY80.4%
TTM EPS YoY103.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-74.9%
Net margin-20.9%
FCF margin-104.8%
EBITDA margin-72.6%

Returns

ROE-38.2%
ROA-8.6%
ROIC (approx.)—
Asset turnover0.41x

Leverage & solvency

Liabilities / assets49.4%
Debt / equity0.00x
Current ratio4.72x
Interest coverage—

Cash quality & payout

Operating cash flow / net income4.95x
Accruals ratio33.8%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$43.77M$6.34M———
R&D expense$56.04M$41.21M$52.14M$59.20M$51.19M
SG&A expense$29.71M$24.78M$27.00M$29.95M$23.86M
Operating income-$41.98M-$60.58M-$79.13M-$89.15M-$75.04M
Pretax income-$35.04M-$58.24M———
Income tax$0$0$0$0$0
Net income-$35.04M-$58.24M-$76.40M-$88.22M-$75.80M
EBITDA-$40.44M-$58.94M-$77.23M-$87.30M-$73.55M
EPS (basic)-4.19-15.24-2.78-3.22-13.52
EPS (diluted)-4.19-15.24-2.78-3.22-13.52
Balance sheet
Cash & equivalents$137.53M$57.07M$46.29M$121.95M$199.61M
Current assets$145.03M$60.23M$48.13M$124.50M$202.52M
PP&E, net$3.89M$4.47M$5.94M$7.25M$7.62M
Total assets$154.69M$71.08M$60.93M$139.16M$218.06M
Current liabilities$56.27M$27.26M$15.96M$21.12M$12.78M
Total liabilities$119.41M$53.48M$24.10M$33.52M$32.63M
Shareholders' equity$35.27M$17.60M$36.83M$105.65M$185.43M
Shares outstanding4.53M3.27M27.61M27.43M27.36M
Cash flow statement
Operating cash flow-$4.99M-$18.38M-$68.62M-$75.72M-$80.75M
Capital expenditure$518,000$36,000$486,000$1.87M$1.10M
Free cash flow-$5.51M-$18.41M-$69.11M-$77.59M-$81.85M
Investing cash flow-$518,000-$36,000-$486,000-$1.87M-$1.10M
Financing cash flow$87.78M$29.20M-$6.55M-$69,000$260.67M
Depreciation & amortization$1.54M$1.64M$1.90M$1.85M$1.50M
Stock-based compensation$6.94M$6.43M$7.38M$8.42M$4.96M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.